Quince Therapeutics, Inc. (QNCX) — SEC Filings
Quince Therapeutics, Inc. (QNCX) — 30 SEC filings. Latest: 8-K (Apr 9, 2026). Includes 13 8-K, 6 10-Q, 4 SC 13G/A.
View Quince Therapeutics, Inc. on SEC EDGAR
Overview
Quince Therapeutics, Inc. (QNCX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 9, 2026: On April 9, 2026, Quince Therapeutics, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation. These amendments, filed under Item 5.03, signify changes to the company's foundational governing documents.
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 3 bearish, 27 neutral. The dominant filing sentiment for Quince Therapeutics, Inc. is neutral.
Filing Type Overview
Quince Therapeutics, Inc. (QNCX) has filed 13 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 1 SC 13D, 1 SC 13G, 1 8-K/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of QNCX's 22 recent filings, 3 were flagged as high-risk, 10 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$13.442M |
| Debt-to-Equity | 102.73 |
| Cash Position | $6.452M |
| Total Debt | $17.520M |
Key Executives
- Dirk Thye, M.D.
- Christopher Lowe
- David A. Lamond
- Antoine Papiernik
- Graziano Seghezzi
- Henriette Richter
- Maina Bhaman
Industry Context
The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Quince Therapeutics rely heavily on innovation and successful clinical trials to bring new therapies to market. The industry is competitive, with substantial investment required to advance drug candidates through various stages of development.
Top Tags
corporate-governance (7) · biotech (7) · 10-Q (4) · financials (4) · amendment (3) · Biotechnology (3) · Quince Therapeutics (3) · Net Loss (2) · R&D Expenses (2) · Cash Burn (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $13.442M | Increased from $5.492M in Q3 2024, indicating widening losses. |
| Net Loss (YTD Sep 2025) | $44.521M | Slightly higher than $44.370M in YTD Sep 2024, showing sustained losses. |
| R&D Expenses (Q3 2025) | $8.083M | Increased from $4.916M in Q3 2024, reflecting higher development costs. |
| Cash and Cash Equivalents (Sep 30, 2025) | $6.452M | Slight increase from $6.212M at Dec 31, 2024, but still very low for a biotech. |
| Short-term Investments (Sep 30, 2025) | $19.836M | Significant decrease from $34.572M at Dec 31, 2024, indicating cash utilization. |
| Total Liabilities (Sep 30, 2025) | $108.840M | Increased from $84.332M at Dec 31, 2024, driven by debt and warrants. |
| Total Stockholders' Equity (Sep 30, 2025) | $1.059M | Drastically reduced from $30.146M at Dec 31, 2024, signaling financial weakness. |
| Current Portion of Debt (Sep 30, 2025) | $17.520M | New liability, indicating significant short-term debt obligations. |
| Warrant Liabilities (Sep 30, 2025) | $14.853M | New liability, reflecting recent financing activities. |
| Common Shares Outstanding (Sep 30, 2025) | 54,494,965 | Increased from 44,001,643 at Dec 31, 2024, indicating significant dilution. |
| Revenue | $0 | No revenue for Q2 2025 and YTD 2025, consistent with prior year, indicating clinical stage. |
| Net Loss (Q2 2025) | -$13.7M | Decreased from -$16.2M in Q2 2024, showing some cost control. |
| Net Loss (YTD 2025) | -$27.9M | Decreased from -$32.9M in YTD 2024, reflecting reduced expenses. |
| R&D Expense Change (YTD) | -19.6% | R&D expenses decreased from $19.6M in YTD 2024 to $16.0M in YTD 2025, potentially impacting pipeline progress. |
| Private Placement Proceeds | $10.0M | Gross proceeds from a June 12, 2025, private placement, providing a capital infusion. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Quince Therapeutics, Inc. (QNCX)?
Quince Therapeutics, Inc. has 30 recent SEC filings from Jan 2024 to Apr 2026, including 13 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of QNCX filings?
Across 30 filings, the sentiment breakdown is: 3 bearish, 27 neutral. The dominant sentiment is neutral.
Where can I find Quince Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Quince Therapeutics, Inc. (QNCX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Quince Therapeutics, Inc.?
Key financial highlights from Quince Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for QNCX?
The investment thesis for QNCX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Quince Therapeutics, Inc.?
Key executives identified across Quince Therapeutics, Inc.'s filings include Dirk Thye, M.D., Christopher Lowe, David A. Lamond, Antoine Papiernik, Graziano Seghezzi and 2 others.
What are the main risk factors for Quince Therapeutics, Inc. stock?
Of QNCX's 22 assessed filings, 3 were flagged high-risk, 10 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Quince Therapeutics, Inc.?
Forward guidance and predictions for Quince Therapeutics, Inc. are extracted from SEC filings as they are enriched.